Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can artery scans let high-risk diabetes patients stop blood thinners sooner?

NCT ID NCT07238764

Completed Disease control Sponsor: Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether people with diabetes and a high risk of bleeding can safely stop taking two blood thinners (DAPT) just one month after getting a special stent, instead of the usual six months. Doctors used a special camera (OCT) to check if the artery had healed enough. The goal was to see if this personalized approach could reduce bleeding without raising the risk of heart attacks or strokes. The study involved 40 participants and compared early stopping to standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
polymer-free amphilimus-eluting stent
What this could lead to
If successful, this approach could allow high-risk patients to stop dual antiplatelet therapy earlier, reducing bleeding risk while still preventing clots.
What could go wrong
This is a small pilot study with only 40 participants, so results may not apply to all patients. The imaging-guided strategy may not prove as safe as standard care in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE DAPT(DUAL ANTIPLATELET THERAPY) DIABETES MELLITUS HIGH BLEEDING RISK PATIENTS

Contacts and locations

Locations

  • Almazov National Medical Research Center of the Ministry of Health of the Russian Federation

    Saint Petersburg, 197341, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.